SI-BONE, Inc. SIBN

SIBN Company Overview

SI-BONE, Inc. is a U.S.-based medical device company focused on minimally invasive surgical solutions for disorders of the sacropelvic anatomy. The company operates within the orthopedic and musculoskeletal medical technology industry, with a primary emphasis on sacroiliac (SI) joint dysfunction, pelvic fixation, and related spinal and pelvic conditions. SI-BONE is best known for its proprietary iFuse implant systems, which are designed to stabilize and fuse the SI joint using minimally invasive surgical techniques. The company generates most of its revenue from the sale of implantable devices and related surgical instrumentation used by orthopedic surgeons, neurosurgeons, and spine specialists.

The company’s principal products include the iFuse Implant System, iFuse-3D, iFuse-TORQ, and related enabling technologies for pelvic fixation and SI joint fusion procedures. SI-BONE’s strategic positioning is tied to its specialization in a clinically underdiagnosed segment of lower back pain and its portfolio of FDA-cleared implants supported by clinical evidence and reimbursement coverage expansion. Founded in 2008 and headquartered in Santa Clara, California, SI-BONE evolved from an early-stage orthopedic device innovator into a publicly traded medical technology company listed on Nasdaq under the ticker SIBN. Its growth has been supported by physician education programs, clinical studies, and expanding adoption of minimally invasive SI joint fusion procedures.